OTLK
Outlook Therapeutics, Inc. Common Stock
stockNASDAQ
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team's biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics' platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company's most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.60 | 2026-10-09 | -18.65% | 8.958 |
| 1M | 0.68 | 2026-09-17 | -28.46% | 5.135 |
| 3M | 1.39 | 2026-07-17 | -64.95% | 1.205 |
| 6M | 0.31 | 2026-04-17 | +57.57% | 0.683 |
| 1Y | 1.31 | 2025-10-17 | -62.81% | 1.064 |
| 2Y | 5.14 | 2024-10-17 | -90.52% | — |
| 5Y | 42.20 | 2021-10-18 | -98.84% | 0.965 |
Outlook Therapeutics, Inc. Common Stock (NASDAQ:OTLK) stock price today is $0.49, and today's volume is 3,117,274. OTLK is down 2.560% today. The 30 day average volume is 4.46M. OTLK market cap is $118.61M with 243.45M shares outstanding.